Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares of the company's stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Jazz Pharmaceuticals Stock Performance
Shares of NASDAQ JAZZ traded up $2.36 during midday trading on Friday, reaching $138.81. The company had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The business's 50-day simple moving average is $127.85 and its 200 day simple moving average is $119.83. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock has a market cap of $8.43 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LSV Asset Management grew its stake in Jazz Pharmaceuticals by 1.5% during the 4th quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock valued at $311,699,000 after purchasing an additional 37,108 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after purchasing an additional 115,102 shares during the period. Dimensional Fund Advisors LP boosted its position in Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after buying an additional 320,724 shares during the last quarter. Capital World Investors boosted its position in Jazz Pharmaceuticals by 5.7% in the fourth quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock valued at $236,860,000 after buying an additional 104,195 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after buying an additional 315,608 shares during the period. Hedge funds and other institutional investors own 89.14% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Piper Sandler restated an "overweight" rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Barclays reissued an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Morgan Stanley restated an "overweight" rating and issued a $183.00 price target (up from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $189.40.
Get Our Latest Research Report on JAZZ
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
